Abstract:Background: Accurate prediction of efficacy of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors is of critical importance. To address this issue, a network meta-analysis (NMA) comparing existing common measurements for curative effect of PD-1/PD-L1 monotherapy was conducted. Methods: We searched PubMed, Embase, the Cochrane Library database, and relevant clinical trials to find out studies published before Feb 22, 2023 that use PD-L1 immunohistochemistry (IHC), tumor mutational burden (TMB), gene expression profiling (GEP), microsatellite instability (MSI), multiplex IHC/immunofluorescence (mIHC/IF), other immunohistochemistry and hematoxylin-eosin staining (other IHC&HE) and combined assays to determine objective response rates to anti–PD-1/PD-L1 monotherapy. Study-level data were extracted from the published studies. The primary goal of this study was to evaluate the predictive efficacy and rank these assays mainly by NMA, and the second objective was to compare them in subgroup analyses. Heterogeneity, quality assessment, and result validation were also conducted by meta-analysis. Findings: 144 diagnostic index tests in 49 studies covering 5322 patients were eligible for inclusion. mIHC/IF exhibited highest sensitivity (0.76, 95% CI: 0.57-0.89), the second diagnostic odds ratio (DOR) (5.09, 95% CI: 1.35-13.90), and the second superiority index (2.86). MSI had highest specificity (0.90, 95% CI: 0.85-0.94), and DOR (6.79, 95% CI: 3.48-11.91), especially in gastrointestinal tumors. Subgroup analyses by tumor types found that mIHC/IF, and other IHC&HE demonstrated high predictive efficacy for non-small cell lung cancer (NSCLC), while PD-L1 IHC and MSI were highly efficacious in predicting the effectiveness in gastrointestinal tumors. When PD-L1 IHC was combined with TMB, the sensitivity (0.89, 95% CI: 0.82-0.94) was noticeably improved revealed by meta-analysis in all studies. Interpretation: Considering statistical results of NMA and clinical applicability, mIHC/IF appeared to have superior performance in predicting response to anti PD-1/PD-L1 therapy. Combined assays could further improve the predictive efficacy. Prospective clinical trials involving a wider range of tumor types are needed to establish a definitive gold standard in future.

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Clinical Applications of PD-L1 Bioassays for Cancer Immunotherapy

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Biomarkers of response to PD-1/PD-L1 inhibition

Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor.

Companion Diagnostics and Predictive Biomarkers for PD-1/PD-L1 Immune Checkpoint Inhibitors Therapy in Malignant Melanoma

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis

Mechanistic Insight of Predictive Biomarkers for Antitumor PD‑1/PD‑L1 Blockade: A Paradigm Shift Towards Immunome Evaluation (Review)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

The Biomarkers of Hyperprogressive Disease in PD-1/PD-L1 Blockage Therapy